Clinical Trials
ConSynance is committed to advancing clinical research for Prader-Willi syndrome and related rare CNS disorders. Our current studies evaluate CSTI-500, an investigational oral therapy designed to address behavioral dysregulation and hyperphagia.
NCT07348601
Phase 2 CSTI-500 in Prader-Willi Syndrome
RECRUITING
Investigational oral therapy evaluating safety, tolerability, pharmacokinetics, and potential effects on behavioral dysregulation and hyperphagia in PWS. Potential participants may include individuals aged 13–50 years with genetically confirmed Prader-Willi syndrome who meet study eligibility requirements.
Interested in participating in this study?
For questions about participation or study eligibility, please contact:
Elizabeth Roof
Vanderbilt University Medical Center
elizabeth.roof@vanderbilt.edu
615-343-3330
Phase: Phase 2
Design: Open-label
Status: Recruiting
Age Range: 13-50 years
Genetic subtype: Chromosome 15 deletion
Location: Vanderbilt University Medical Center
Sponsor: ConSynance Therapeutics, Inc.
CSTI-500 is an investigational therapy and has not been approved by the FDA or other regulatory authorities. Participation in clinical research is voluntary and eligibility criteria apply.
NCT05504395
Phase 1 CSTI-500 Pharmacokinetic and Safety Study in Prader-Willi Syndrome
COMPLETED
This Phase 1 clinical study evaluated the pharmacokinetics and safety of a single oral dose of CSTI-500 in individuals with genetically confirmed Prader-Willi syndrome. The study was conducted at Vanderbilt University Medical Center and supported advancement of CSTI-500 into Phase 2 development.
Phase: Phase 1
Design: Open-label, single-center, single-dose
Status: Completed
Age Range: 13-50 years
Location: Vanderbilt University Medical Centre
Sponsor: ConSynance Therapeutics, Inc.